Search Results - "SCHUCHTER, Lynn"

Adjuvant Melanoma Therapy — Head-Spinning Progress by Schuchter, Lynn M

“…Every year in the United States, approximately 87,000 patients receive the diagnosis of melanoma. Although most of these patients are cured with simple…”
Get full text

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade by Benci, Joseph L., Xu, Bihui, Qiu, Yu, Wu, Tony J., Dada, Hannah, Twyman-Saint Victor, Christina, Cucolo, Lisa, Lee, David S.M., Pauken, Kristen E., Huang, Alexander C., Gangadhar, Tara C., Amaravadi, Ravi K., Schuchter, Lynn M., Feldman, Michael D., Ishwaran, Hemant, Vonderheide, Robert H., Maity, Amit, Wherry, E. John, Minn, Andy J.

“…Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling…”
Get full text

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response by Chen, Gang, Huang, Alexander C., Zhang, Wei, Zhang, Gao, Wu, Min, Xu, Wei, Yu, Zili, Yang, Jiegang, Wang, Beike, Sun, Honghong, Xia, Houfu, Man, Qiwen, Zhong, Wenqun, Antelo, Leonardo F., Wu, Bin, Xiong, Xuepeng, Liu, Xiaoming, Guan, Lei, Li, Ting, Liu, Shujing, Yang, Ruifeng, Lu, Youtao, Dong, Liyun, McGettigan, Suzanne, Somasundaram, Rajasekharan, Radhakrishnan, Ravi, Mills, Gordon, Lu, Yiling, Kim, Junhyong, Chen, Youhai H., Dong, Haidong, Zhao, Yifang, Karakousis, Giorgos C., Mitchell, Tara C., Schuchter, Lynn M., Herlyn, Meenhard, Wherry, E. John, Xu, Xiaowei, Guo, Wei

“…Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1…”
Get full text

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion by Khan, Omar, Giles, Josephine R., McDonald, Sierra, Manne, Sasikanth, Ngiow, Shin Foong, Patel, Kunal P., Werner, Michael T., Huang, Alexander C., Alexander, Katherine A., Wu, Jennifer E., Attanasio, John, Yan, Patrick, George, Sangeeth M., Bengsch, Bertram, Staupe, Ryan P., Donahue, Greg, Xu, Wei, Amaravadi, Ravi K., Xu, Xiaowei, Karakousis, Giorgos C., Mitchell, Tara C., Schuchter, Lynn M., Kaye, Jonathan, Berger, Shelley L., Wherry, E. John

“…Exhausted CD8 + T (T ex ) cells in chronic infections and cancer have limited effector function, high co-expression of inhibitory receptors and extensive…”
Get full text

Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms by Beltra, Jean-Christophe, Manne, Sasikanth, Abdel-Hakeem, Mohamed S., Kurachi, Makoto, Giles, Josephine R., Chen, Zeyu, Casella, Valentina, Ngiow, Shin Foong, Khan, Omar, Huang, Yinghui Jane, Yan, Patrick, Nzingha, Kito, Xu, Wei, Amaravadi, Ravi K., Xu, Xiaowei, Karakousis, Giorgos C., Mitchell, Tara C., Schuchter, Lynn M., Huang, Alexander C., Wherry, E. John

“…CD8+ T cell exhaustion is a major barrier to current anti-cancer immunotherapies. Despite this, the developmental biology of exhausted CD8+ T cells (Tex)…”
Get full text

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial by Weber, Jeffrey S, Prof, Gibney, Geoff, MD, Sullivan, Ryan J, MD, Sosman, Jeffrey A, Prof, Slingluff, Craig L, Prof, Lawrence, Donald P, MD, Logan, Theodore F, MD, Schuchter, Lynn M, Prof, Nair, Suresh, MD, Fecher, Leslie, MD, Buchbinder, Elizabeth I, MD, Berghorn, Elmer, BSN, Ruisi, Mary, MD, Kong, George, PhD, Jiang, Joel, PhD, Horak, Christine, PhD, Hodi, F Stephen, Dr

“…Summary Background Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in…”
Get full text

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer by Twyman-Saint Victor, Christina, Rech, Andrew J., Maity, Amit, Rengan, Ramesh, Pauken, Kristen E., Stelekati, Erietta, Benci, Joseph L., Xu, Bihui, Dada, Hannah, Odorizzi, Pamela M., Herati, Ramin S., Mansfield, Kathleen D., Patsch, Dana, Amaravadi, Ravi K., Schuchter, Lynn M., Ishwaran, Hemant, Mick, Rosemarie, Pryma, Daniel A., Xu, Xiaowei, Feldman, Michael D., Gangadhar, Tara C., Hahn, Stephen M., Wherry, E. John, Vonderheide, Robert H., Minn, Andy J.

“…In this study, involving melanoma patients and a mouse model for melanoma, an optimal anti-tumour response was induced by using a combination of radiation with…”
Get full text

Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy by Zhang, Ying, Kurupati, Raj, Liu, Ling, Zhou, Xiang Yang, Zhang, Gao, Hudaihed, Abeer, Filisio, Flavia, Giles-Davis, Wynetta, Xu, Xiaowei, Karakousis, Giorgos C., Schuchter, Lynn M., Xu, Wei, Amaravadi, Ravi, Xiao, Min, Sadek, Norah, Krepler, Clemens, Herlyn, Meenhard, Freeman, Gordon J., Rabinowitz, Joshua D., Ertl, Hildegund C.J.

“…How tumor-infiltrating T lymphocytes (TILs) adapt to the metabolic constrains within the tumor microenvironment (TME) and to what degree this affects their…”
Get full text

Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma by Ma, Xiao-Hong, Piao, Sheng-Fu, Dey, Souvik, McAfee, Quentin, Karakousis, Giorgos, Villanueva, Jessie, Hart, Lori S, Levi, Samuel, Hu, Janice, Zhang, Gao, Lazova, Rossitza, Klump, Vincent, Pawelek, John M, Xu, Xiaowei, Xu, Wei, Schuchter, Lynn M, Davies, Michael A, Herlyn, Meenhard, Winkler, Jeffrey, Koumenis, Constantinos, Amaravadi, Ravi K

“…Melanomas that result from mutations in the gene encoding BRAF often become resistant to BRAF inhibition (BRAFi), with multiple mechanisms contributing to…”
Get full text

Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma by Rangwala, Reshma, Chang, Yunyoung C, Hu, Janice, Algazy, Kenneth M, Evans, Tracey L, Fecher, Leslie A, Schuchter, Lynn M, Torigian, Drew A, Panosian, Jeffrey T, Troxel, Andrea B, Tan, Kay-See, Heitjan, Daniel F, DeMichele, Angela M, Vaughn, David J, Redlinger, Maryann, Alavi, Abass, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, O'Dwyer, Peter J, Amaravadi, Ravi K

“…The combination of temsirolimus (TEM), an MTOR inhibitor, and hydroxychloroquine (HCQ), an autophagy inhibitor, augments cell death in preclinical models. This…”
Get full text

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response by Huang, Alexander C., Postow, Michael A., Orlowski, Robert J., Mick, Rosemarie, Bengsch, Bertram, Manne, Sasikanth, Xu, Wei, Harmon, Shannon, Giles, Josephine R., Wenz, Brandon, Adamow, Matthew, Kuk, Deborah, Panageas, Katherine S., Carrera, Cristina, Wong, Phillip, Quagliarello, Felix, Wubbenhorst, Bradley, D’Andrea, Kurt, Pauken, Kristen E., Herati, Ramin S., Staupe, Ryan P., Schenkel, Jason M., McGettigan, Suzanne, Kothari, Shawn, George, Sangeeth M., Vonderheide, Robert H., Amaravadi, Ravi K., Karakousis, Giorgos C., Schuchter, Lynn M., Xu, Xiaowei, Nathanson, Katherine L., Wolchok, Jedd D., Gangadhar, Tara C., Wherry, E. John

“…Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical…”
Get full text

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma by Huang, Alexander C., Orlowski, Robert J., Xu, Xiaowei, Mick, Rosemarie, George, Sangeeth M., Yan, Patrick K., Manne, Sasikanth, Kraya, Adam A., Wubbenhorst, Bradley, Dorfman, Liza, D’Andrea, Kurt, Wenz, Brandon M., Liu, Shujing, Chilukuri, Lakshmi, Kozlov, Andrew, Carberry, Mary, Giles, Lydia, Kier, Melanie W., Quagliarello, Felix, McGettigan, Suzanne, Kreider, Kristin, Annamalai, Lakshmanan, Zhao, Qing, Mogg, Robin, Xu, Wei, Blumenschein, Wendy M., Yearley, Jennifer H., Linette, Gerald P., Amaravadi, Ravi K., Schuchter, Lynn M., Herati, Ramin S., Bengsch, Bertram, Nathanson, Katherine L., Farwell, Michael D., Karakousis, Giorgos C., Wherry, E. John, Mitchell, Tara C.

“…Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by 3 weeks. It is…”
Get full text

ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression by Zhang, Wei, Zhong, Wenqun, Wang, Beike, Yang, Jiegang, Yang, Jingbo, Yu, Ziyan, Qin, Zhiyuan, Shi, Alex, Xu, Wei, Zheng, Cathy, Schuchter, Lynn M., Karakousis, Giorgos C., Mitchell, Tara C., Amaravadi, Ravi, Herlyn, Meenhard, Dong, Haidong, Gimotty, Phyllis A., Daaboul, George, Xu, Xiaowei, Guo, Wei

“…Tumor-derived extracellular vesicles (TEVs) suppress the proliferation and cytotoxicity of CD8+ T cells, thereby contributing to tumor immune evasion. Here, we…”
Get full text

Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer by Kwak, Taekyoung, Wang, Fang, Deng, Hui, Condamine, Thomas, Kumar, Vinit, Perego, Michela, Kossenkov, Andrew, Montaner, Luis J., Xu, Xiaowei, Xu, Wei, Zheng, Cathy, Schuchter, Lynn M., Amaravadi, Ravi K., Mitchell, Tara C., Karakousis, Giorgos C., Mulligan, Charles, Nam, Brian, Masters, Gregory, Hockstein, Neil, Bennett, Joseph, Nefedova, Yulia, Gabrilovich, Dmitry I.

“…Here, we report that functional heterogeneity of macrophages in cancer could be determined by the nature of their precursors: monocytes (Mons) and monocytic…”
Get full text

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma by FLAHERTY, Keith T, LEE, Sandra J, FENGMIN ZHAO, SCHUCHTER, Lynn M, FLAHERTY, Lawrence, KEFFORD, Richard, ATKINS, Michael B, LEMING, Philip, KIRKWOOD, John M

“…The primary objective of this study was to determine whether carboplatin, paclitaxel, and sorafenib (CPS) improve overall survival (OS) compared with…”
Get full text

Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy by Mohiuddin, Jahan J, Chu, Brian, Facciabene, Andrea, Poirier, Kendra, Wang, Xingmei, Doucette, Abigail, Zheng, Cathy, Xu, Wei, Anstadt, Emily J, Amaravadi, Ravi K, Karakousis, Giorgos C, Mitchell, Tara C, Huang, Alexander C, Shabason, Jacob E, Lin, Alexander, Swisher-McClure, Samuel, Maity, Amit, Schuchter, Lynn M, Lukens, John N

“…Abstract Background Gut microbial diversity is associated with improved response to immune checkpoint inhibitors (ICI). Based on the known detrimental impact…”
Get full text

Oncologist phenotypes and associations with response to a machine learning-based intervention to increase advance care planning: Secondary analysis of a randomized clinical trial by Li, Eric, Manz, Christopher, Liu, Manqing, Chen, Jinbo, Chivers, Corey, Braun, Jennifer, Schuchter, Lynn Mara, Kumar, Pallavi, Patel, Mitesh S, Shulman, Lawrence N, Parikh, Ravi B

“…While health systems have implemented multifaceted interventions to improve physician and patient communication in serious illnesses such as cancer, clinicians…”
Get full text

PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer by Rebecca, Vito W, Nicastri, Michael C, Fennelly, Colin, Chude, Cynthia I, Barber-Rotenberg, Julie S, Ronghe, Amruta, McAfee, Quentin, McLaughlin, Noel P, Zhang, Gao, Goldman, Aaron R, Ojha, Rani, Piao, Shengfu, Noguera-Ortega, Estela, Martorella, Alessandra, Alicea, Gretchen M, Lee, Jennifer J, Schuchter, Lynn M, Xu, Xiaowei, Herlyn, Meenhard, Marmorstein, Ronen, Gimotty, Phyllis A, Speicher, David W, Winkler, Jeffrey D, Amaravadi, Ravi K

“…Clinical trials repurposing lysosomotropic chloroquine (CQ) derivatives as autophagy inhibitors in cancer demonstrate encouraging results, but the underlying…”
Get more information

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma by Mehnert, Janice M, Mitchell, Tara C, Huang, Alexander C, Aleman, Tomas S, Kim, Benjamin J, Schuchter, Lynn M, Linette, Gerald P, Karakousis, Giorgos C, Mitnick, Sheryl, Giles, Lydia, Carberry, Mary, Frey, Noelle, Kossenkov, Andrew, Groisberg, Roman, Hernandez-Aya, Leonel F, Ansstas, George, Silk, Ann W, Chandra, Sunandana, Sosman, Jeffrey A, Gimotty, Phyllis A, Mick, Rosemarie, Amaravadi, Ravi K

“…Autophagy is a resistance mechanism to BRAF/MEK inhibition in BRAFV600-mutant melanoma. Here we used hydroxychloroquine (HCQ) to inhibit autophagy in…”
Get full text

Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline by WONG, Sandra L, BALCH, Charles M, DIRK NOYES, R, SCHUCHTER, Lynn M, VALSECCHI, Matias E, WEAVER, Donald L, LYMAN, Gary H, HURLEY, Patricia, AGARWALA, Sanjiv S, AKHURST, Timothy J, COCHRAN, Alistair, CORMIER, Janice N, GORMAN, Mark, KIM, Theodore Y, MCMASTERS, Kelly M

“…The American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO) sought to provide an evidence-based guideline on the use of lymphatic…”
Get full text